Stryker/$SYK
Stryker stock dropped after executives warned that persistent supply-chain disruptions in its peripheral vascular and joint replacement operations would continue into H2.
13 hours agoLightyear AI
1D1W1MYTD1Y5YMAX
Capital at risk
About Stryker
Stryker designs, manufactures, and markets an array of medical equipment, instruments, consumable supplies, and implantable devices. The product portfolio includes hip and knee replacements, extremities, endoscopy systems, operating room equipment, embolic coils, mechanical thrombectomy systems, hospital beds and gurneys, and orthopedic robotics. Stryker remains one of the three largest competitors in reconstructive orthopedic implants and holds the leadership position in operating room equipment. Roughly one-fourth of Stryker's total revenue currently comes from outside the United States.
- Ticker
- $SYK
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 56,000
- Headquarters
- Portage, United States
- Website
- www.stryker.com
Stryker Metrics
BasicAdvanced
$106B
28.65
$9.65
0.77
$3.48
1.27%
Price and volume
Market cap
$106B
Beta
0.77
52-week high
$395.90
52-week low
$275.10
Average daily volume
2.5M
Dividend rate
$3.48
Financial strength
Current ratio
2.157
Quick ratio
1.08
Long term debt to equity
59.163
Total debt to equity
64.391
Dividend payout ratio (TTM)
35.32%
Interest coverage (TTM)
10.22%
Profitability
EBITDA (TTM)
7,376
Gross margin (TTM)
65.59%
Net profit margin (TTM)
14.43%
Operating margin (TTM)
23.82%
Effective tax rate (TTM)
27.56%
Revenue per employee (TTM)
$460,000
Management effectiveness
Return on assets (TTM)
8.16%
Return on equity (TTM)
16.51%
Valuation
Price to earnings (TTM)
28.647
Price to revenue (TTM)
4.096
Price to book
4.42
Price to tangible book (TTM)
-79.25
Price to free cash flow (TTM)
22.505
Free cash flow yield (TTM)
4.44%
Free cash flow per share (TTM)
12.283
Dividend yield (TTM)
1.26%
Forward dividend yield
1.27%
Growth
Revenue change (TTM)
8.48%
Earnings per share change (TTM)
27.79%
3-year revenue growth (CAGR)
9.92%
10-year revenue growth (CAGR)
9.45%
3-year earnings per share growth (CAGR)
10.87%
10-year earnings per share growth (CAGR)
8.57%
3-year dividend per share growth (CAGR)
5.72%
10-year dividend per share growth (CAGR)
8.89%
What the Analysts think about Stryker
Analyst ratings (Buy, Hold, Sell) for Stryker stock.
Analyst projections of the future price of Stryker stock.
Bulls say / Bears say
Second-quarter 2026 performance showed strong recovery, with reported sales up 9.4%, organic sales up 9.0%, adjusted EPS up 17.9%, and adjusted operating margin expanding 170 basis points to 27.4%. (SEC earnings release)
Management narrowed full-year 2026 guidance to 8.3%–9.3% organic sales growth and $14.95–$15.10 adjusted EPS, indicating confidence that underlying demand and operational execution can sustain high-single-digit growth. (SEC earnings release)
Stryker completed its $435 million acquisition of Amplitude Vascular Systems in May 2026, adding a next-generation intravascular lithotripsy platform and expanding its peripheral vascular portfolio into complex peripheral arterial disease. (SEC filing)
Stryker missed Wall Street’s first-quarter 2026 revenue and profit estimates, with Reuters citing softer demand for implants and devices used in complex spinal and orthopedic procedures. (Reuters)
The March 11, 2026 cybersecurity incident created operational and financial uncertainty; Stryker reported idle production time related to the incident and warned that its effects could materially and adversely affect results. (SEC filing)
Stryker expects an unfavorable product mix for the foreseeable future as faster growth in lower-gross-margin MedSurg and Neurotechnology outpaces Orthopaedics; higher manufacturing and supply-chain costs could further pressure profitability. (SEC filing)
Data summarised monthly by Lightyear AI. Last updated on 8 Sept 2026.
Stryker Financial Performance
Revenues and expenses
Stryker Earnings Performance
Company profitability
Upcoming events
Stryker News
AllArticlesVideos
Funds containing Stryker
AllEURGBPUSD
Fund name | Fund size | $SYK weighting |
|---|---|---|
iShares S&P 500 Health Care Sector€IUHE | €125M | 1.98% |
iShares MSCI World Health Care Sector Advanced€CBUF | €606M | 1.95% |
iShares AI Adopters and Applications€AIAA | €169M | 1.84% |
iShares AI Adopters and Applications£AIAA | £145M | 1.84% |
iShares MSCI USA SRI$SUAS | $3.4B | 0.81% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.